Antiendothelial cell antibodies in inflammatory myopathies: Distribution among clinical and serologic groups and association with interstitial lung disease

D'Cruz D., Keser G., Khamashta M. A., Direskeneli H., Targoff I. N., Miller F., ...Daha Fazla

Journal of Rheumatology, cilt.27, sa.1, ss.161-164, 2000 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 1
  • Basım Tarihi: 2000
  • Dergi Adı: Journal of Rheumatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.161-164
  • Marmara Üniversitesi Adresli: Evet

Özet

Objective. To determine the prevalence and associations of antiendothelial cell antibodies (AECA) in a well characterized cohort of patients with idiopathic inflammatory myopathies (IIM). Methods. Clinical characteristics, AECA, and myositis-specific autoantibodies were assessed by standard methods in 56 subjects with IIM. Results. AECA were found in 20/56 patients with IIM, were seen in all the major clinical and serologic IIM groups, and were found in 10/15 patients with interstitial lung disease (ILD) (chi squared 6.5, p < 0.01 with Yates' correction, relative risk 2.7, specificity 86% and sensitivity 50%). Antisynthetase antibodies, also associated with ILD as described (chi squared = 26.5, p < 0.001 with Yates' correction, relative risk 8.7, specificity 95%, sensitivity 77%), did not correlate with the presence of AECA. Conclusion. AECA appear to be present in all forms of IIM and are markers for ILD that are independent of anti- synthetase autoantibodies. AECA may be a useful serologic marker for ILD in IIM.